Clinical Trial Update: Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the mechanism of action of galiximab in previously untreated follicular non-Hodgkin's lymphoma; the trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Galiximab (galiximab)

Snippet

Sponsor: Biogen | Conditions: Lymphoma, Non-Hodgkin's | Phase 1 | Status: TERMINATED